Skip to main content
. 2011 Feb 16;2011(2):CD008794. doi: 10.1002/14651858.CD008794.pub2
OR
RE Model 
 
Standard Dose
Model
Median (95% CI)
Unadjusted
Model
Median (95% CI)
Dose Adjusted
Model
Median (95% CI)
Abatacept 0.97 (0.40 to 2.31) 1.19 (0.62 to 2.27) 1.08 (0.48 to 2.48)
Adalimumab 1.23 (0.65 to 2.40) 1.26 (0.74 to 2.20) 1.30 (0.73 to 2.42)
Anakinra 4.05 (1.22 to 16.84)* 3.96 (1.27 to 15.75)* 4.03 (1.29 to 16.22)*
Certolizumab 4.75 (1.52 to 18.45)* 4.65 (1.61 to 16.22)* 4.67 (1.58 to 16.15)*
Etanercept 1.29 (0.72 to 2.45) 1.19 (0.72 to 2.01) 1.28 (0.73 to 2.30)
Golimumab 1.11 (0.45 to 2.59) 1.30 (0.65 to 2.65) 1.14 (0.49 to 2.55)
Infliximab 1.41 (0.75 to 2.62) 1.58 (1.08 to 2.36)* 1.17 (0.65 to 2.09)
Rituximab 0.26 (0.03 to 2.16) 1.17 (0.76 to 1.85) 0.46 (0.16 to 1.15)
Tocilizumab 0.84 (0.20 to 3.56) 1.52 (0.72 to 3.32) 0.78 (0.22 to 2.60)
Overall 1.37 (1.04 to 1.82)*    
Data points
Residual deviance
DIC
(115)
123.2
494.12
(163)
221.8
895.53
(208)
221.5
902.03